On September 9, Microlight Gene officially announced the completion of the Pre-A round of financing of more than 100 million yuan. Yuanhang Capital and Huafang Capital co-led the investment, and various investment institutions such as Yifeng Zhuohua Fund, King Ling Investment, Guangzhou Disruptive Fund, and Nanjing Innovation Investment Group participated in the investment. This round of financing will mainly be used for the continuous clinical development of innovative epigenetic drugs for clinical treatment of chronic diseases.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.